SCHEMBL5568328

SCHEMBL5568328

O=C(O)c1cn(-c2ccc(F)cc2F)c2cc(N3CCC(CCCC4CCNCC4)CC3)c(F)nc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
LMNA P02545 6/20 0.46
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 5/20 0.46
HSD17B10 Q99714 5/20 0.46
TOP2A P11388 2/20 0.42
TOP2B Q02880 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
EPHA2 P29317 1/20 0.41
FLT4 P35916 1/20 0.41
GSK3B P49841 1/20 0.41
RARB P10826 1/20 0.41
TBXAS1 P24557 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HTT P42858 2/20 0.40
BRD4 O60885 1/20 0.40
TSHR P16473 1/20 0.40
CYP2J2 P51589 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571721 0.87 LMNA (0.58) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL5568331 0.82 KMT2A (0.67) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL8322470 0.78 KMT2A (0.49) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL5571970 0.77 ALDH1A1 (0.44) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL8324565 0.76 KMT2A (0.49) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL3132964 0.73 EPHA2 (0.46) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL29557013 0.73 ALDH1A1 (0.80) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL10657099 0.73 ALDH1A1 (0.80) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL8621440 0.69 LMNA (0.57) KMT2ALMNAKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL8554393 0.69 LMNA (0.58) KMT2ALMNAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730154-B1 RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES CUMBRE IP VENTURES L P (US) 2012-10-17 EP disclosed
US-7247634-B2 Rifamycin derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-07-24 US disclosed
EP-1730154-A2 RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES Cumbre Pharmaceuticals Inc. (US) 2006-12-13 EP disclosed
US-20050261262-A1 Rifamycin derivatives effective against drug-resistant microbes CUMBRE INC. (US) 2005-11-24 US disclosed
WO-2005070940-A2 RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES CUMBRE PHARMACEUTICALS INC. (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261262-A1 Rifamycin derivatives effective against drug-resistant microbes RIF1, MRPL37, AURKAIP1 KMT2A 3269/4885LMNA 2569/4885KDM4E 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.